Barrick Mining Corporation (B)vsGlaxoSmithKline PLC ADR (GSK)
B
Barrick Mining Corporation
$43.13
+3.08%
BASIC MATERIALS · Cap: $70.27B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 93% more annual revenue ($32.78B vs $16.96B). B leads profitability with a 29.4% profit margin vs 17.8%. GSK appears more attractively valued with a PEG of 0.50. B earns a higher WallStSmart Score of 78/100 (B+).
B
Strong Buy78
out of 100
Grade: B+
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.9%
Fair Value
$316.39
Current Price
$43.13
$273.26 discount
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 52.6%
Revenue surging 64.5% year-over-year
Earnings expanding 150.0% YoY
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Keeps 29 of every $100 in revenue as profit
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : B
The strongest argument for B centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 52.6%. Revenue growth of 64.5% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : B
The primary concerns for B are PEG Ratio.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
B profiles as a growth stock while GSK is a value play — different risk/reward profiles.
B carries more volatility with a beta of 1.07 — expect wider price swings.
B is growing revenue faster at 64.5% — sustainability is the question.
B generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
B scores higher overall (78/100 vs 66/100), backed by strong 29.4% margins and 64.5% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Barrick Mining Corporation
BASIC MATERIALS · GOLD · USA
Barnes Group Inc. provides engineering products, industrial technologies, and solutions in the United States and internationally. The company is headquartered in Bristol, Connecticut.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other GOLD Stocks
Want to dig deeper into these stocks?